Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
Aligos Therapeutics (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to developing therapies for liver and viral diseases, announced it will release its third quarter 2024 financial results on November 6, 2024, after the U.S. markets close. The announcement will provide insights into the company's financial performance during this period.
Aligos Therapeutics (Nasdaq: ALGS), un'azienda biofarmaceutica in fase clinica dedicata allo sviluppo di terapie per malattie epatiche e virali, ha annunciato che rilascerà i risultati finanziari del terzo trimestre del 2024 il 6 novembre 2024, dopo la chiusura dei mercati statunitensi. L'annuncio fornirà informazioni sulle performance finanziarie dell'azienda durante questo periodo.
Aligos Therapeutics (Nasdaq: ALGS), una empresa biofarmacéutica en etapa clínica dedicada al desarrollo de terapias para enfermedades hepáticas y virales, anunció que publicará sus resultados financieros del tercer trimestre de 2024 el 6 de noviembre de 2024, después del cierre de los mercados en EE.UU. El anuncio proporcionará información sobre el rendimiento financiero de la empresa durante este período.
알리고스 테라퓨틱스(나스닥: ALGS)는 간 및 바이러스 질환 치료제를 개발하는 데 전념하는 임상 단계의 생명공학 회사로, 2024년 11월 6일 미국 시장 종료 후 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 이 발표는 이 기간 동안 회사의 재무 성과에 대한 통찰력을 제공할 것입니다.
Aligos Therapeutics (Nasdaq: ALGS), une entreprise biopharmaceutique en phase clinique dédiée au développement de thérapies pour les maladies du foie et les maladies virales, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le 6 novembre 2024, après la fermeture des marchés américains. Cette annonce fournira des informations sur la performance financière de l'entreprise pendant cette période.
Aligos Therapeutics (Nasdaq: ALGS), ein biopharmazeutisches Unternehmen in klinischen Phasen, das sich der Entwicklung von Therapien für Leber- und Viruskrankheiten widmet, gab bekannt, dass es am 6. November 2024 nach Schließung der US-Märkte seine finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlichen wird. Die Bekanntgabe wird Einblicke in die finanzielle Leistung des Unternehmens in diesem Zeitraum bieten.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), Aligos a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s third quarter 2024 financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, and the impact of global events and other macroeconomic conditions on the Aligos business. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Company
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
(650) 910-0427
jtarazi@Aligos.com
FAQ
When will Aligos Therapeutics announce its Q3 2024 financial results?
What is the focus of Aligos Therapeutics?
What is the stock symbol for Aligos Therapeutics?
